Alphabet, Takeda, ShangPharma and Amgen were among the investors in gene and cell therapy startup Obsidian Therapeutics' $49.5m series A round.
GV, a corporate venturing subsidiary of internet technology conglomerate Alphabet, has led a $49.5m series A round for US-based cell and gene therapy developer Obsidian Therapeutics that closed yesterday.
Takeda Ventures and Amgen Ventures, respective subsidiaries of pharmaceutical firms Takeda and Amgen, also took part in the round, as did ShangPharma Investment Group, the corporate venturing vehicle for pharmaceutical holding company ShangPharma.
The other participants in the round were Alexandria Venture Investments, the strategic investment arm of life sciences real…